Business
Annual Report & Notice of AGM
Annual Report & Notice of AGM.
About this update from Hvivo Plc
[{"type":"text","content":"\n\nhVIVO plc\n(\"hVIVO\" or the \"Company\")\n \nAnnual Report & Notice of AGM\n \nhVIVO plc (AIM & Euronext: HVO), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, confirms that the Company's Annual Report and Accounts for the year ended 31 December 2023 and the Notice of Annual General Meeting (\"AGM\") will be posted to shareholders today.\n \nThe 2023 Annual Report and Accounts, the Notice of AGM and accompanying form of proxy are available to download from the Company's website www.hvivo.com.\n \nThe Annual General Meeting will be held at the offices of DAC Beachcroft LLP, 25 Walbrook, London EC4N 8AF, United Kingdom on 13 May 2024 at 11am (BST).\n \nFor further information please contact:\n \n\n\n\n\nhVIVO plc\n\n\n+44 (0) 20 7756 1300\n\n\n\n\nYamin 'Mo' Khan, Chief Executive Officer\nStephen Pinkerton, Chief Financial Officer\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCavendish Capital Markets Limited (Nominated Adviser and Joint Broker)\n\n\n+44 (0) 20 7220 0500\n\n\n\n\nGeoff Nash, Charlie Beeson, Nigel Birks, Harriet Ward\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nPeel Hunt LLP (Joint Broker)\n\n\n+44 (0)20 7418 8900\n\n\n\n\nJames Steel, Dr Christopher Golden\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nDavy (Euronext Growth Adviser and Joint Broker)\n\n\n+353 (0) 1 679 6363\n\n\n\n\nAnthony Farrell, Niall Gilchrist\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nWalbrook PR (Financial PR & IR)\nStephanie Cuthbert / Phillip Marriage /\nLouis Ashe-Jepson\n\n\n+44 (0) 20 7933 8780 or [email protected]\n+44 (0) 7796 794 663 / +44 (0) 7867 984 082 /\n+44 (0) 7747 515 393\n\n\n\n\n\n\n\n\n\n\n\n \n \nNotes to Editors\n \nAbout hVIVO\n \nhVIVO plc (ticker: HVO) (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. The Group provides end-to-end early clinical development services to its large, established and growing repeat client base, which includes four of the top 10 largest global biopharma companies.\n \nThe Group's fast-growing services business includes a unique portfolio of 11 human challe...